← board
CVSI
distress 5/10 · elevated risk$0.020%today-78% from 52w high
Revenue
pre-revenue
Liquidity
$0M
Runway
1.4 yrs
Shares 1y
+11%
Price & events
-50.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.0%
1W
+0.0%
1M
-33.3%
3M
-50.0%
6M
-50.0%
1Y
-66.7%
2Y
-93.9%
5Y
-95.8%
All
Overview
- Market Cap
- $4.08M
- Enterprise Value
- $3.77M
- Volume
- 305.80K
- 52 Week Range
- $0.02 – $0.09
- Total Shares
- 203.98M
- Float Shares
- 188.09M
- % Held by Insiders
- 7.79%
- % Held by Institutions
- 0.00%
- RVOL
- 0.38x
- Beta
- 0.44
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 2
- 2024-11-15partnershipDefinitive agreement to acquire Extract Labs, a manufacturer of premium cannabinoid products.SEC 8-K
- 2024-09-30partnershipEntered strategic partnership with Chewy to offer pet products on chewy.com.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.